Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
BeiGene
Eisai Inc.
AbbVie
AbbVie
National Cancer Institute (NCI)
Duke University
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)